|
1
|
Jung C, Kim RS, Zhang HJ, Lee SJ and Jeng
MH: HOXB13 induces growth suppression of prostate cancer cells as a
repressor of hormone-activated androgen receptor signaling. Cancer
Res. 64:9185–9192. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Edwards S, Campbell C, Flohr P, Shipley J,
Giddings I, Te-Poele R, Dodson A, Foster C, Clark J, Jhavar S, et
al: Expression analysis onto microarrays of randomly selected cDNA
clones highlights HOXB13 as a marker of human prostate cancer. Br J
Cancer. 92:376–381. 2005. View Article : Google Scholar
|
|
3
|
Ma XJ, Wang Z, Ryan PD, Isakoff SJ,
Barmettler A, Fuller A, Muir B, Mohapatra G, Salunga R, Tuggle JT,
et al: A two-gene expression ratio predicts clinical outcome in
breast cancer patients treated with tamoxifen. Cancer Cell.
5:607–616. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Miao J, Wang Z, Provencher H, Muir B,
Dahiya S, Carney E, Leong CO, Sgroi DC and Orsulic S: HOXB13
promotes ovarian cancer progression. Proc Natl Acad Sci USA.
104:17093–17098. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Economides KD and Capecchi MR: Hoxb13 is
required for normal differentiation and secretory function of the
ventral prostate. Development. 130:2061–2069. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Economides KD, Zeltser L and Capecchi MR:
Hoxb13 mutations cause overgrowth of caudal spinal cord and tail
vertebrae. Dev Biol. 256:317–330. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kim YR, Oh KJ, Park RY, Xuan NT, Kang TW,
Kwon DD, Choi C, Kim MS, Nam KI, Ahn KY, et al: HOXB13 promotes
androgen independent growth of LNCaP prostate cancer cells by the
activation of E2F signaling. Mol Cancer. 9:1242010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim YR, Kim IJ, Kang TW, Choi C, Kim KK,
Kim MS, Nam KI and Jung C: HOXB13 downregulates intracellular zinc
and increases NF-κB signaling to promote prostate cancer
metastasis. Oncogene. 33:4558–4567. 2014. View Article : Google Scholar
|
|
9
|
Dzau VJ, Braun-Dullaeus RC and Sedding DG:
Vascular proliferation and atherosclerosis: New perspectives and
therapeutic strategies. Nat Med. 8:1249–1256. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kennett SB, Udvadia AJ and Horowitz JM:
Sp3 encodes multiple proteins that differ in their capacity to
stimulate or repress transcription. Nucleic Acids Res.
25:3110–3117. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jung C, Kim RS, Lee SJ, Wang C and Jeng
MH: HOXB13 homeodomain protein suppresses the growth of prostate
cancer cells by the negative regulation of T-cell factor 4. Cancer
Res. 64:3046–3051. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lee SJ, Lee K, Yang X, Jung C, Gardner T,
Kim HS, Jeng MH and Kao C: NFATc1 with AP-3 site binding
specificity mediates gene expression of
prostate-specific-membrane-antigen. J Mol Biol. 330:749–760. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schreiber M, Kolbus A, Piu F, Szabowski A,
Möhle-Steinlein U, Tian J, Karin M, Angel P and Wagner EF: Control
of cell cycle progression by c-Jun is p53 dependent. Genes Dev.
13:607–619. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xiong Y, Hannon GJ, Zhang H, Casso D,
Kobayashi R and Beach D: p21 is a universal inhibitor of cyclin
kinases. Nature. 366:701–704. 1993. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
el-Deiry WS, Tokino T, Velculescu VE, Levy
DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and
Vogelstein B: WAF1, a potential mediator of p53 tumor suppression.
Cell. 75:817–825. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Parker SB, Eichele G, Zhang P, Rawls A,
Sands AT, Bradley A, Olson EN, Harper JW and Elledge SJ:
p53-independent expression of p21Cip1 in muscle and other
terminally differentiating cells. Science. 267:1024–1027. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Angel P and Karin M: The role of Jun, Fos
and the AP-1 complex in cell-proliferation and transformation.
Biochim Biophys Acta. 1072:129–157. 1991.PubMed/NCBI
|
|
18
|
Behrens A, Sibilia M and Wagner EF:
Amino-terminal phosphorylation of c-Jun regulates stress-induced
apoptosis and cellular proliferation. Nat Genet. 21:326–329. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fan Y, Chen H, Qiao B, Liu Z, Luo L, Wu Y
and Yin Z: c-Jun NH2-terminal kinase decreases ubiquitination and
promotes stabilization of p21(WAF1/CIP1) in K562 cell. Biochem
Biophys Res Commun. 355:263–268. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim GY, Mercer SE, Ewton DZ, Yan Z, Jin K
and Friedman E: The stress-activated protein kinases p38 alpha and
JNK1 stabilize p21(Cip1) by phosphorylation. J Biol Chem.
277:29792–29802. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kardassis D, Papakosta P, Pardali K and
Moustakas A: c-Jun transactivates the promoter of the human
p21WAF1/Cip1 gene by acting as a superactivator of the
ubiquitous transcription factor Sp1. J Biol Chem. 274:29572–29581.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tang F, Kokontis J, Lin Y, Liao S, Lin A
and Xiang J: Androgen via p21 inhibits tumor necrosis factor
alpha-induced JNK activation and apoptosis. J Biol Chem.
284:32353–32358. 2009. View Article : Google Scholar : PubMed/NCBI
|
